EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Treatment Decisions for Resectable Non–Small-Cell Lung Cancer: Balancing Less With More?

David O'Reilly iD, Angela Botticella, Simon Barry, Seamus Cotter, Jessica S Donington, Cecile Le Pechoux, Jarushka Naidoo iD

American Society of Clinical Oncology Educational Book · 2023-05 · (43)

DOI: 10.1200/edbk_389950 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Society of Clinical Oncology Educational Book, 2023-05. Verfasst von David O'Reilly und 6 weiteren Autor:innen. Beteiligte Einrichtung: Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 79 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For patients with non–small-cell lung cancer (NSCLC), the outcomes for patients with resectable disease are historically poor compared with other solid organ malignancies. In recent years, there have been significant advances in multidisciplinary care, which have resulted in improved outcomes. Innovations in surgical oncology include the use of limited resection and minimally invasive techniques. Recent data in radiation oncology have suggested refinements in pre- and postoperative radiation therapy, resulting in optimization of techniques in the curative setting. Finally, the success of immune checkpoint inhibitors and targeted therapies in the advanced setting has paved the way for inclusion in the adjuvant and neoadjuvant settings, resulting in recent regulatory approvals for four regimens (CheckMate-816, IMpower010, PEARLS, ADAURA). In this review, we will provide an overview of the seminal studies informing advancements in optimal surgical resection, radiation treatment, and systemic therapy for resectable NSCLC. We will summarize the key data on survival outcomes, biomarker analyses, and future directions for perioperative studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansNeoadjuvant TherapyImmune Checkpoint Inhibitors

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Beaumont RCSI Cancer Centre, Beaumont Hospital, Dublin, Ireland.
  • RCSI StAR MD Programme, Bon Secours Hospital, Glasnevin, Dublin, Ireland.
  • Department of Radiation Oncology, Gustave Roussy Cancer Campus University Hospital, Villejuif, France.
  • Cancer Trials Ireland, Ardilaun Court, St Stephen's Green, Dublin, Ireland.
  • Department of Surgery, Section of Thoracic Surgery, University of Chicago Medicine & Biologic Sciences, Chicago, IL.
  • RCSI University of Health Sciences, Dublin, Ireland.

ORCID-Profile: David O'Reilly, Jarushka Naidoo

Zitieren

APA

O'Reilly, D., Botticella, A., Barry, S., Cotter, S., Donington, J. S., Le Pechoux, C., & Naidoo, J. (2023). Treatment Decisions for Resectable Non–Small-Cell Lung Cancer: Balancing Less With More?. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_389950

Vancouver

O'Reilly D, Botticella A, Barry S, Cotter S, Donington JS, Le Pechoux C, et al. Treatment Decisions for Resectable Non–Small-Cell Lung Cancer: Balancing Less With More?. American Society of Clinical Oncology Educational Book. 2023. doi:10.1200/edbk_389950

BibTeX
@article{OReilly2023,
  author = {O'Reilly, David and Botticella, Angela and Barry, Simon and Cotter, Seamus and Donington, Jessica S and Le Pechoux, Cecile and Naidoo, Jarushka},
  title = {Treatment Decisions for Resectable Non–Small-Cell Lung Cancer: Balancing Less With More?},
  journal = {American Society of Clinical Oncology Educational Book},
  year = {2023},
  number = {43},
  doi = {10.1200/edbk_389950}
}
Kostenlos starten →